Tirzepatide: A New Treatment for Diabetes - Frankly Speaking Ep 285

<p>Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: <a href='https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-285'>https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-285</a></p> <p>Overview: Join us for a closer look at tirzepatide, a first-in-class glucose-dependent insulinotropic peptide (GIP) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA). See how this novel glucose-lowering agent can help raise the bar in both HbA1c lowering and weight loss in patients with type 2 diabetes mellitus.</p> <p>Episode resource links:</p> <ul><li>Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 May 17:1–11.</li> </ul> <p>Guest: Alan Ehrlich MD, FAAFP   Music Credit: Richard Onorato</p>